The following results were based on our recent clinical studies on sulfamethoxazole (SMX) and trimethoprim (TMP) combination product in the pediatric field.
1. The majority of freshly isolated Staphylococcus aureus strains including those resistant to tetracycline was found to be sensitive to this combination product.
2. After oral administration, both SMX and TMP were well absorbed through the intestinal tract. Plasma levels of the compounds reached peak during the 2nd and 5th hours post-administration. Concentrations of bacteriologically active substances excreted in urine was found to be markedly high.
3. The clinical effect of the combination product in acute respiratory infections was excellent.
4. In the treatment of scarlet fever, this combination product rapidly normalized temperature and β-hemolytic streptococci in the throat cultures promptly disappeared. Positive conversion of throat culturesafter the cessation of treatment was relatively frequent, however.
5. In the treatment of diarrhea in infants and children, this combination product normalized the fecal findings within 3 to 4 days.
6. Patients with quasi-dysentery symptomatology without positive stool cultures were promptly responsive to the combination. Patients infected with Shigella sonnei which was resistant to streptomycin, tetracycline and chloramphenicol, clinically improved by normalization of fecal findings and frequency of defecation, but eradication of pathogenic organisms was difficult in most cases.
7. This combination product was highly effective in cystitis caused by Escherichia coli.
